TY  - JOUR
AU  - Rivero-Menendez, Olga
AU  - Soto-Debran, Juan Carlos
AU  - Cuenca-Estrella, Manuel
AU  - Alastruey-Izquierdo, Ana
PY  - 2021
DO  - 10.3390/jof7030232
UR  - http://hdl.handle.net/20.500.12105/13033
AB  - Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of...
LA  - eng
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
KW  - Aspergillus
KW  - CLSI
KW  - EUCAST
KW  - Antifungals
KW  - Cryptic
KW  - Cyp51A
KW  - Ibrexafungerp
TI  - In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies.
TY  - journal article
ER  -